









Armida Gigante
Sr Manager Sustainability Western Europe

Medtronic

Charline Wurzer

Partner - Central Europe Lead for ESG in HC


BCG

Elia Tziambazis

MD & Partner - Global Co-Lead for ESG in HC



Healthcare accounts for 5% of global emissions



5% of global emissions

3 different types of emissions categories



Scope 1 Direct emissions

Sources owned or controlled by company



Scope2

Indirect emissions

Generating energy used by company



Scope 3


All other emissions

Due to company, but from sources not owned or controlled by company

5% of global emissions

3 emissions categories

Scope 3 drives 70-90% of Healthcare emissions




5% of global emissions

3 emissions categories

Scope 3 70-90% of HC emissions

Many different climate goals described



5% of global emissions

3 emissions categories

Scope 3 70-90% of HC emissions

Many different climate goals described

Few MedTech companies have set net-zero targets



Of MedTech companies have set scope 1, 2 and 3 net zero target (based on top 20 MedTech)



Of Pharma companies have scope 1, 2 and 3 net-zero goals (based on top 10 Pharma)

5% of global emissions


3 emissions categories

Scope 3 70-90% of HC emissions

Many different climate goals described

Few MedTech companies with net-zero targets

~50% abatement can be achieved with 3 levers



5% of global emissions

3 emissions categories

Scope 3 70-90% of HC emissions

Many different climate goals described

Few MedTech companies with net-zero targets

~50% abatement can be achieved with 3 levers

Climate actions can be cost neutral

Up to 30%

Of emissions could be abated in ways that generate a net cost saving



Of emissions could be cut in a cost neutral way

Climate is only one of nine planetary boundaries


Climate Change (C02 & GHG)

Biosphere Integrity (food and water demands)

Land Use Change (deforestation)

Freshwater Use (surface water and groundwater)

Biogeochemical Flows (Phosphates, Nitrogen)



Novel entities (plastics, chemicals)

Stratospheric Ozone Depletion (CFCs, halon)

Atmospheric Aerosol Loading (pesticides)

Ocean Acidification (CO2 emissions)

SBTN & TNFD defining Nature assessment and disclosure





Company's impact on the planet






























































Planet's impact on company






















































GSK aiming for Net Zero and Nature positive

2025

2030

2045



- 100% renewable electricity (Sc 2)
- 80% emissions reduction
- 20% nature-based solutions

Net zero value chain (all scopes)



- 100% sites to stewardship
- 20% reduction in overall water use
- achieve good water Water neutral in operations and with key suppliers in water-stressed regions
 - Zero impact API for all sites and key suppliers



- Zero operational waste including SUPs
- 25% environmental impact reduction for products and packaging
- 10% waste reduction from supply chain



- Positive impact on biodiversity at all sites
- 100% of natural raw materials sustainably sourced and deforestation free

High ambition for sustainable sourcing



of agricultural, forestry and marine derived materials are sustainably sourced and deforestation free by 2030

'Full chain of custody' trace from producers to processors





Crop, Marine, Livestock, Poultry and Processor

Adopting existing globally recognised third-party standards where available

GSK is driving change through the ecosystem







Examples



GSK started with a bold ambition and built gradually



Set a bold ambition, even without line of sight on full delivery plan



Started with Climate where capabilities (and guidance) more mature



Progressed key climate initiatives before focusing on Nature



Working on areas with biggest footprint impact and clearest solution



Identifying remaining gaps, developing plans, and iterating often

Let's take a closer look at waste

Climate Change (C02 & GHG)

Biosphere Integrity (food and water demands)

Land Use Change (deforestation)

Freshwater Use (surface water and groundwater)

Biogeochemical Flows (Phosphates, Nitrogen)



Novel entities (plastics, chemicals), i.e. most of this ends up as WASTE

Stratospheric Ozone Depletion (CFCs, halon)

Atmospheric Aerosol Loading (pesticides)

Ocean Acidification (CO2 emissions)

Waste is a major challenge for MedTech

3.5kg

waste per hospital bed per day in highincome countries

13kg

of hospital waste per patient per day in the US



Circularity can help us tackle this challenge



Circularity offers several additional benefits

Product example: Insulin pen

Use of recycled Redesign materials packaging 15-25%





Cost reduction

Carbon reduction





Additional business benefits



Increase supply chain resilience



Enable use of higher quality components



Drive **product** differentiation







Accelerate patient access and equity

85M patient lives improved annually by FY25



Foster inclusion, diversity & equity

45% representation of women in manager and above roles globally and 30% from ethnically diverse groups in manager and above roles in the U.S. by FY26



Further environmental sustainability

50% reduction of green gas emissions by FY25 and net zero emissions across our value chain by FY45



A healthy planet is essential to human health. Furthering environmental sustainability with an enterprise business strategy to directly advance our Mission to be a good corporate citizenship

Medtronic

Product stewardship | Circularity needs to balance quality, safety, compliance and also sustainability

Reduce waste for diabetes products



Extended infusion insulin tubing set be worn twice as long as standard set, saving on average 3-4 lb of plastic per patient yearly

Reduce waste in surgery



Signia[™] stapling system allows:

- 66% reduction in clinical waste in open and minimally invasive procedures
- 90% less material impact to produce
- Multiuse of the handle up to 300 times






To realize these targets, Medtronic has set up a dedicated Sustainability Development Center


Medtronic

Safe recycling | Where feasible, we recollect products at end-of-use to be safely recycled, refurbished or reprocessed

Example in Cardiac Rhythm Management:

Refurbishment & redeployment of patient monitors & accessories





Medtronic

Five main learnings on driving sustainability in MedTech



Define strategy with clear targets and KPIs for measuring performance



Set up **governance & coordination mechanisms** that allow for effective cross-functional collaboration across whole organization



Foster **end-to-end** cultural change and create a sense of urgency for environmental sustainability




Collaborate with Regulators to define a **sustainable roadmap** for change



Partner with customers, MedTech players & researchers to identify clinical practices that improve patient outcomes & sustainability





Four steps to get from talk to action



1. Set ambition

Define circularity ambition level (comply, compete, lead) and define KPIs



Select product(s)

Select initial product (categories) maximizing waste and carbon savings potential

Four steps to get from talk to action



1. Set ambition

Define circularity ambition level (comply, compete, lead) and define KPIs



Select product(s)

Select initial product (categories) maximizing waste and carbon savings potential



3. Assess and prioritize levers


Create transparency on circularity potential along the full value cycle

Identify circularity levers and simulate impact


Prioritize based on impact and ease of implementation

Translate levers into concrete initiatives

Assess levers | Levers span entire product life cycle



Prioritize levers | Levers to be prioritized based on impact and ease of implementation





Design



Use



Four steps to get from talk to action



1. Set ambition

Define circularity ambition level (comply, compete, lead) and define KPIs



Select product(s)

Select initial product (categories) maximizing waste and carbon savings potential



3. Assess and prioritize levers

Create transparency on circularity potential along the full value cycle

Identify circularity levers and simulate impact

Prioritize based on impact and ease of implementation

Translate levers into concrete initiatives



4. Scale

In case of diverse portfolio:

Extend approach to other product categories and distill learnings

Setup initiative tracking

Include circularity principles into processes, e.g. product dev.

Embed circularity into organization, e.g. via circularity champions and incentives linked to circularity KPIs

Many thanks for attending our session - do you have any questions?



Armida Gigante

Sr Manager Sustainability Western Europe, Medtronic armida.gigante@medtronic.com



Elia Tziambazis

Managing Director & Partner, BCG London Tziambazis. Elia@bcg.com



Charline Wurzer

Partner, BCG Munich Wurzer.Charline@bcg.com

BOSTON CONSULTING GROUP bcg.com